N. Regamey (Bern, Switzerland), M. Muhlebach (Chapel Hill, Nc, United States of America)
LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF)
D. B. Bilton, P. R. Robinson, P. C. Cooper, B. C. Charlton (London, United Kingdom; Melbourne, Sydney, Australia)
|  |
Cystic fibrosis heelprick among a newborn population in the Netherlands: the CHOPIN study
J. Dankert-Roelse, A. Vernooij-van Langen, G. Loeber, B. Elvers, R. Triepels, H. Gille, C. van der Ploeg, S. Reijntjens, E. Dompeling (Amsterdam, Heerlen, Bilthoven, Tilburg, Leiden, Netherlands)
|  |
Ventilation distribution is not influenced by structural lung disease in infants with cystic fibrosis (CF) diagnosed following newborn screening (NBS)
G. Hall, G. Nolan, K. Logie, S. Schulzke, C. Murray, S. Stick, S. Ranganathan, P. Robinson, P. Sly, AREST CF (Perth, Melbourne, Australia)
| |
Neutrophilic inflammation predisposes to structural lung disease in cystic fibrosis (CF) via neutrophil elastase activity
P. Sly, C. Gangell, N. De Klerk, S. Ranganathan, C. F. Arest (Perth, Melbourne, Australia)
|  |
Improved survival at low lung function in cystic fibrosis (CF)
P. George, N. Pareek, D. Bilton, W. Banya, M. Hodson (London, United Kingdom)
| |
Safety and efficacy of inhaled human α-1 antitrypsin (AAT) in cystic fibrosis: a report of a phase II clinical study
E. Kerem, S. Bauer, P. Strauss, N. Jaffe, S. Armoni, T. Pugatsch, D. Shoseyov, N. Tov (Jerusalem, Rehovot, Israel)
| |
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients
P. Bruinenberg, J. Wilson, D. Serisier, B. Otulana, J. Blanchard (Hayward, United States Of America; Melbourne, Brisbane, Australia)
| |
Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers
M. Freissmuth, X. Koenig, C. Gloeckel (Vienna, Austria)
| |